Technical Coverage on Biotechnology Equities -- Galena Biopharma, Eleven Biotherapeutics, Relypsa, and Amgen

Jul 20, 2016, 07:40 ET from Chelmsford Park SA

NEW YORK, July 20, 2016 /PRNewswire/ --

The Biotech arena continues to grapple with research and development costs, drug approvals, and high medicine prices. Additionally, the upcoming U.S. elections and its outcome might have a huge impact on the entire industry. This morning, takes a look at four stocks in this space for further evaluation: Galena Biopharma Inc. (NASDAQ: GALE), Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), and Amgen Inc. (NASDAQ: AMGN). Sign up today and access our notes for free at:

Galena Biopharma 

San Ramon, California Galena-based biopharmaceutical company, Biopharma Inc.'s shares dropped 5.36%, closing Tuesday's trading session at $0.38. The stock recorded a trading volume of 4.25 million shares. The Company's shares are trading 71.27% below their 200-day moving average. Additionally, shares of Galena Biopharma, which focuses on developing and commercializing oncology therapeutics that address major unmet medical needs, have a Relative Strength Index (RSI) of 25.40.

On July 11th, 2016, research firm Maxim Group reiterated its 'Buy' rating with a decrease of the target price to $2 a share from $4 a share for the Company's stock.

On July 11th, 2016, Galena Biopharma announced the closing of its previously announced sale to certain institutional investors of 28,000,000 shares of common stock at a purchase price per share of $0.45 in a registered direct offering, and warrants to purchase up to 14,000,000 shares of common stock with an exercise price of $0.65 per share in a concurrent private placement. The net proceeds are expected to be approximately $11.7 million, which the company intends to use to fund its clinical trials of its product candidates, to augment its working capital, and for general corporate purposes. Free notes on GALE are available at:

Eleven Biotherapeutics 

On Tuesday, Cambridge, Massachusetts-based Eleven Biotherapeutics Inc.'s stock recorded a trading volume of 1.16 million shares and ended the day 2.77% lower at $2.46. The Company's shares have advanced 5.58% in the last month and 246.48% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 38.41% and 49.12%, respectively. Furthermore, shares of Eleven Biotherapeutics, which engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States, have an RSI of 59.52.

On July 08th, 2016, Eleven Biotherapeutics announced that its Investigational New Drug application for EBI-031, a humanized monoclonal antibody that potently binds interleukin-6 and inhibits all known forms of IL-6 cytokine signaling, for treatment of ocular diseases, has become effective. As a result of the achievement of this milestone, Eleven Biotherapeutic is entitled to receive a $22.5 million payment from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. pursuant to the terms of its license agreement with Roche signed on June 13th, 2016. The complimentary note on EBIO can be accessed at:


Redwood City, California headquartered Relypsa Inc.'s stock finished the day 2.02% lower at $19.84 and with a total volume of 1.38 million shares traded. The Company's shares have advanced 10.84% in the last one month and 12.92% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 12.09% and 5.62%, respectively. Additionally, shares of Relypsa have an RSI of 58.42.

On July 18th, 2016, Relypsa, announced that the compensation committee of the company's board of directors has granted 2 new employees options to purchase an aggregate of 5,700 shares of the company's common stock with a per share exercise price of $20.67, the closing trading price on the grant date, and 2,850 restricted stock units. Visit us today and access our complete notes on RLYP at:


Shares in California headquartered biotechnology company, Amgen Inc., ended yesterday's session 0.27% lower at $162.49 and with a total volume of 2.25 million shares traded. The stock has advanced 8.60% in the last one month, 0.90% in the previous three months, and 1.46% since the start of this year. The Company's shares are trading 5.18% above their 50-day moving average and 6.37% above their 200-day moving average. Moreover, shares of Amgen, which engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide, have an RSI of 66.30.

On June 29th, 2016, research firm Bernstein initiated a 'Market Perform' rating for the Company's stock.

On July 3rd, 2016, Amgen announced that the European Commission has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The EC approved the extended indication for Kyprolis based on data from the Phase 3 head-to-head ENDEAVOR trials. The approval by the EC follows the U.S. Food and Drug Administration's approval of a supplemental New Drug Application based on the ENDEAVOR results in January 2016. Get free access to your notes on AMGN at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA